(NASDAQ: CTMX) Cytomx Therapeutics's forecast annual revenue growth rate of 33.86% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.84%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.9%.
Cytomx Therapeutics's revenue in 2026 is $18,302,000.On average, 9 Wall Street analysts forecast CTMX's revenue for 2026 to be $6,670,768,680, with the lowest CTMX revenue forecast at $3,203,119,475, and the highest CTMX revenue forecast at $12,286,251,128. On average, 9 Wall Street analysts forecast CTMX's revenue for 2027 to be $9,054,804,747, with the lowest CTMX revenue forecast at $3,416,660,773, and the highest CTMX revenue forecast at $19,378,872,823.
In 2028, CTMX is forecast to generate $9,143,707,654 in revenue, with the lowest revenue forecast at $1,281,247,790 and the highest revenue forecast at $19,378,872,823.